Unicycive Therapeutics, Inc. june 10, 2025 Please complete the form below to contact Kaplan Fox regarding the Unicycive Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Announces an Investigation into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Unicycive investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. On June 10, 2025, before the market opened, Unicycive issued a press release announcing an “update on its New Drug Application (NDA) for oxlanthanum carbonate (OLC) to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.” The press release stated that the U.S. Federal Drug Administration (“FDA”) “communicated to the Company that it had identified deficiencies in cGMP compliance at a third-party manufacturing vendor (one of its CDMO’s third-party subcontractors and not its Drug Substance vendor) following an FDA inspection. The FDA indicated that, given the identified deficiencies, any label discussions between the FDA and the Company are precluded. The Company has responded to all FDA information requests and expects a final decision from the FDA by the PDUFA action date of June 28, 2025.” Following this news, the price of Unicycive stock fell as much as $0.43 per share, over 47%, during intraday trading on June 10, 2025 on unusually heavy volume. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Fortrea Holdings, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Abacus Global Management, Inc. See the Case Red Cat Holdings, Inc. See the Case Ibotta, Inc. See the Case Krispy Kreme, Inc. See the Case UroGen Pharma Ltd. See the Case Iovance Biotherapeutics, Inc. See the Case 1-800-Flowers.com See the Case Compass Diversified Holdings See the Case SelectQuote and GoHealth, Inc. See the Case Take-Two Interactive Software, Inc. See the Case
